Three considerations before advising 5-α-reductase inhibitors for chemoprevention

Journal of Clinical Oncology

Volumn 27, Issue 20, 2009, Pages

  Walsh, Patrick C ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; ENZYME INHIBITOR; STEROID 5ALPHA REDUCTASE;

CANCER MORTALITY; CANCER PREVENTION; DIGITAL RECTAL EXAMINATION; DOCTOR PATIENT RELATION; FOOD AND DRUG ADMINISTRATION; LETTER; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK REDUCTION; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; MALE; MEDICAL SOCIETY; NOTE; ONCOLOGY; PRACTICE GUIDELINE; PROSTATE TUMOR; UNITED STATES;

ENZYME INHIBITORS; HUMANS; MALE; MEDICAL ONCOLOGY; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; SOCIETIES, MEDICAL; TESTOSTERONE 5-ALPHA-REDUCTASE; UNITED STATES;

EID: 70249126559     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.9070     Document Type: Letter

References (3)

1. Kramer BS, Hagerty KL, Justman S, et al: Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/ American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol 27:1502-1516, 2009
2. Wilt T, MacDonald R, Hagerty K, et al: 5-α-Reductase Inhibitors for prostate cancer prevention. Cochrane Database Syst Rev 2:CD007091, 2008
3. Thompson IM, Pauler AD, Chi C, et al: Prediction of prostate cancer for patients receiving finasteride: Results from the Prostate Cancer Prevention Trial. J Clin Oncol 25:3076-3081, 2007